Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Sclerosis
Description
A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve. MeSH
Hierarchy View
Phase 3 Indicated Drugs (16)
Phase 2 Indicated Drugs (32)
Other Experimental Indicated Drugs (4)
Organization Involved with Phase 4 Indications (110)
Adolphe Rothschild Ophtalmologic Foundation
Amphia Hospital Breda, the Netherlands
Badalona Hospital Germans Trias i Pujol
Cantonal Hospital of St. Gallen
Federal University of Sao Paulo
Innovatiefonds Zorgverzekeraars
Instituto Mexicano del Seguro Social
Katholieke Universiteit Leuven
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
MidAmerica Research Foundation
MS Center of Northeastern New York
Multiple Sclerosis Center of Atlanta
Multiple Sclerosis Center of Northeastern New York
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Neurocenter of Southern Switzerland, Lugano
Patient-Centered Outcomes Research Institute
Postgraduate Institute of Medical Education and Research
Social Security Mexican Institute
St. Antonius Hospital, Nieuwegein
State University of New York, Buffalo
The University of Texas, Dallas
Organization Involved with Phase 3 Indications (264)
Advanced Neurology Specialists
Advanced Neurosciences Institute
Alabama Neurology Associates, PC
Alta Bates Summit Medical Center
Altru Health System Research Center
Anne Arundel Health System Research Institute
Arizona Neurological Institute
Assistance Publique - Hôpitaux de Paris
Axiom Clinical Research of Florida
Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System
Central Jutland Regional Hospital
Central Texas Neurology Consultants
Centre Hospitalier Universitaire de Nīmes
Collaborative Medicinal Development Pty Limited
Hoosier Cancer Research Network
Hospital of Central Denmark Region, Viborg, Denmark
Hospital of South West Jutland
Icahn School of Medicine at Mount Sinai
Institut fur Klinische Forschung, Germany
Island Neurological Associates, PC
Istituto Don Carlo Gnocchi Divisione Neurologica Riabilitativa. Via Capecelatro 66 20148 Milano
Italian Multiple Sclerosis Foundation
Japan Agency for Medical Research and Development
Josephson Wallack Munshower Neurology, PC
Mazandaran University of Medical Sciences
Medical University of South Carolina
Mercy Multiple Sclerosis Center of Oklahoma Mercy Neuroscience Institute
Multiple Sclerosis Society of Canada
National Cancer Institute (NCI)
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Neurological Disorders and Stroke (NINDS)
Negroski, Stein, Sutherland and Hanes Neurology
Neurology Center of New England P.C.
North Central Neurology Associates, PC
Oregon Health and Science University
Ospedale Maggiore San Giovanni Bosco
Ospedale SAntonio Abate Servizio recupero Neurologico
Phoenix Neurological Associates, LTD
Policlinico Universitario Centro Sclerosi Multipla
Presbyterian/St. Luke's Medical Center, Denver
Princess Beatrix Muscle Foundation
Rivermead Rehabilitation Centre
Royal Berkshire and Battle Hospitals NHS Trust
Ruan Neurology Clinical Research Center
Russian State Medical University
Sibyl E. Wray, MD, Neurology, PC
South Shore Neurologic Associates
Springfield Neurology Associates, LLC
State University of New York, Syracuse
Suncoast Neuroscience Associates, Inc.
The Immune Response Corporation
The Multiple Sclerosis Center of Vero Beach
The Multiple Sclerosis National Competence Centre
The Neurological Institute, PA
The Norwegian Multiple sclerosis Society
Universidad Autonoma de Madrid
University of British Columbia
University of California, San Diego
University of Colorado, Denver
University of Missouri, Kansas City
University of Modena and Reggio Emilia
University of Nice Sophia Antipolis
University of Roma La Sapienza
University of Southern California
University of Texas, San Antonio
Vestre Viken Ringerike Sykehus
Organization Involved with Phase 2 Indications (289)
Advancell - Advanced In Vitro Cell Technologies, S.A.
Alberta Innovates Health Solutions
ALS Therapy Development Institute
Andalusian Initiative for Advanced Therapies
Andalusian Initiative in Advanced Therapies
Barnet and Chase Farm Hospitals NHS Trust
Basildon and Thurrock University Hospitals NHS Foundation Trust
Bennett, James P., Jr., M.D., Ph.D.
Brain Chemistry Labs, Institute for EthnoMedicine
Buffalo Neuroimaging Analysis Center
Catholic University of Sacred Heart, Rome
Center for Neurologic Study, La Jolla, California,
Chinese Academy of Medical Sciences
City of Hope National Medical Center
Clinica Universidad de Navarra
Clinique de sclérose en plaques et neuromusculaire de l'Outaouais
Consortium of Multiple Sclerosis Centers
Danish Research Centre for Magnetic Resonance
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano
Forbes Norris MDA/ALS Research Center
Fundación Universidad Católica de Valencia San Vicente Mártir
Genesis Institute of Cellular Medicine
German Federal Ministry of Education and Research
Health Sciences Centre Foundation, Manitoba
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Institut d'Investigacions Biomèdiques August Pi i Sunyer
IRCCS National Neurological Institute C. Mondino Foundation
Isfahan neurosciences research center
Istituto Biostrutture e Immagini, CNR Naples
Manitoba Medical Service Foundation
Methodist Cancer Center, Houston, Texas
Multiple Sclerosis Society of Great Britain and Northern Ireland
Muscular Dystrophy Association
National Center for Complementary and Integrative Health (NCCIH)
National Center of Neurology and Psychiatry, Japan
National Institute for Health Research, United Kingdom
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Neuraltus Pharmaceuticals, Inc.
NeuroCure Clinical Research Center
Neurogen Brain and Spine Institute
Novo Cellular Medicine Institute LLP
Office of Dietary Supplements (ODS)
Ontario Institute for Regenerative Medicine (OIRM)
Polski Bank Komorek Macierzystych JSC (PBKM)
Pontificia Universidad Catolica de Chile
Rocky Mountain MS Research Group
Royal Brisbane & Women's Hospital
Rudolph Rupert Scleroderma Program
Salford Royal Foundation NHS Trust
Scleroderma Research Consultants LLC
South-Eastern Norway Regional Health Authority
Southend University Hospital Foundation NHS Trust
The Danish Multiple Sclerosis Society
The Multiple Sclerosis Center of Atlanta
The Tuberous Sclerosis Association
Universidad Autonoma de Barcelona
University Hospital Motol, Prague, Czech Republilc
University of Alabama, Birmingham
University of Campania Luigi Vanvitelli
University of Eastern Piedmont
University of Naples Frederico II
Wenatchee Valley Medical Center
Western Institute for Biomedical Research, Salt Lake City, UT
ZonMw: The Netherlands Organisation for Health Research and Development
Organization Involved with Phase 1 Indications (67)
Case Western Reserve University
Centre for Probe Development and Commercialization
Cognitive Research Corporation
Deutsches Zentrum für Neurodegenerative Erkrankungen e. V.
Fondazione Italiana Sclerosi Multipla
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Hospital e Maternidade Dr. Christóvão da Gama
Institute for Neurodegenerative Disorders
Pavlov First Saint Petersburg State Medical University
Organization Involved with Other Experimental Indications (37)
Fonden for scleroseramte paa Fyn
Fundación Neumologica Colombiana
Kessler Medical Rehabilitation Research and Education Corporation
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
